Adaptive Biotechnologies
Adaptive Bio Initiates Strategic Review, Considers Separation of MRD, Immune Medicine Businesses
Premium
While reporting its Q3 earnings results, Adaptive said it hired Goldman Sachs to perform "a review of strategic alternatives" for its MRD and immune medicine businesses.
Adaptive Biotechnologies, BeiGene Partner for Lymphoid Malignancy Drug Development
Adaptive’s ClonoSeq assay will be used to assess MRD across BeiGene’s pipeline of treatments for patients with lymphoid malignancies.
People in the News at Agilent Technologies, ASHG, Veracyte, Enzo Biochem, Renalytix, More
Executive appointments, promotions, and departures in omics and molecular diagnostics for the week of Sept. 4, 2023
People in the News at Adaptive Biotechnologies, Talis Biomedical, PreludeDx, BC Platforms
Executive and academic appointments, promotions, and departures in omics and molecular diagnostics for the week of July 31, 2023.
Adaptive Biotechnologies Sees ClonoSeq Test Volume Grow, Reports 12 Percent Revenue Growth for Q2
During the quarter, the Seattle-based company reported total revenues of $48.9 million, beating analysts' consensus estimate of $44.9 million.
May 5, 2022